Treatment Trends and Key Data Emerging in Myelodysplastic Syndrome After ASH 2024 - Episode 4
Clinical Implications of FDA Approval of Luspatercept for Anemia in ESA-Naive Lower-Risk MDS
Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, on the FDA approval of luspatercept in ESA-naive lower-risk MDS.
Video Player is loading.
Related Content:
